‌

US Patent 11510939 RNAs for complement inhibition

Patent 11510939 was granted and assigned to Apellis Pharmaceuticals on November, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent

Patent attributes

Patent Applicant

Apellis Pharmaceuticals

Current Assignee

Apellis Pharmaceuticals

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

11510939

Date of Patent

November 29, 2022

Patent Application Number

16853732

Date Filed

April 20, 2020

Patent Primary Examiner

CPC Code

RNAs, such as miRNA and siRNA, and their use in treating complement-mediated disorders, are described.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11510939 RNAs for complement inhibition

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API